BSECompany Update29 Jul 2026 · 29 Jul 2026, 10:56 am
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltd · 500124
✦ AI Summary
Dr Reddy's Laboratories Ltd clarifies a news article published in Business Standard regarding the company's antibiotic getting Thailand approval six months after US nod. The company confirms the accuracy of the news and states that it does not constitute a material event or information requiring disclosure under Regulation 30 of SEBI Listing Regulation.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Dr Reddys Laboratories Ltd - 500124 - Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Attachments (1)
📄pdf
Download →
43a14d2f-508f-4578-a655-1c7ec96b4f15.pdf
View document text
Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com
July 29, 2026
BSE Surveillance
BSE Limited (Scrip Code: 500124)
Dear Sir/Madam,
Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, (SEBI Listing Regulation) – Clarification sought by stock exchanges on news item
appearing in “Media/Publication”
Ref: Verification - July 28, 2026 - Dr Reddy’s Laboratories Ltd vide email dated July 28, 2026
This is with reference to your e-mail dated July 28, 2026, on the captioned subject, seeking clarification
from the Company regarding a news article published in Business Standard https://www.business-
standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-
nod-126072700632_1.html on July 28, 2026 with the heading “Dr Reddys antibiotic gets Thailand
approval six months after US nod".
In this connection, we wish to inform that the above captioned news item headline is correct, and the
Company hereby clarify that the above said news pertains to the Company’s joint press release with Global
Antibiotic Research & Development Partnership Foundation (“GARDP”) made on July 27, 2026 titled as
“Thai FDA approves NUZOLVENCE® (zoliflodacin) just six months after US authorization.”
We would also like to inform you that the above-mentioned matter does not constitute a material event or
information requiring disclosure under Regulation 30 of the SEBI Listing Regulation.
Please note that the Company, in compliance with Regulation 30 of the SEBI Listing Regulations, makes
timely disclosures of all events and information considered material and warrants disclosure under the said
Regulations.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR